Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed based on the Company's versatile and robust ADAPTIRâ„¢ modular protein technology platform. The ADAPTIR platform is capable of generating
…More highly differentiated bispecific antibodies with unique mechanisms of action for the treatment of different types of cancer